ArticleThe Plant cell2026
RIN4 fragments released by AvrRpt2 promote NDR1-dependent activation of RPS2.
Article in The Plant cell, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A guardian angel: how immune factor RPS2 is activated by pathogen effector AvrRpt2.The Plant cell · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Plant nucleotide-binding, leucine-rich-repeat (NLR) immune receptors recognize pathogen effectors and activate immunity. The NLR Resistance to Pseudomonas syringae2 (RPS2) recognizes Avirulence protein interacting with RPS2 (AvrRpt2), a Pseudomonas effector that promotes virulence by proteolytically cleaving a membrane-tethered host protein, RPM1-interacting protein 4 (RIN4). RIN4 cleavage by AvrRpt2 also activates RPS2. A model in which RPS2 is activated by elimination of RIN4 is consistent with the ectopic activity of RPS2 in plants lacking RIN4 but does not explain the link between AvrRpt2's virulence activity and RPS2 activation. We found that non-membrane-tethered RIN4 derivatives are potent cytosolic activators of RPS2. Activation of RPS2 by these RIN4 derivatives, like AvrRpt2-induced activation,and unlike ectopic activation in the absence of RIN4, requires the defense signaling protein NON-RACE-SPECIFIC DISEASE RESISTANCE 1 (NDR1). Cleavage products of RIN4 produced by AvrRpt2 play contrasting roles in the activation of RPS2, with the membrane-tethered C-terminal fragment suppressing RPS2 and the non-membrane-tethered internal fragment, dependent on compatibility with the C-terminal fragment, overcoming its suppression of RPS2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.